Elanco Long-Acting Transdermal Buprenorphine for Cats Gains U.S. Approval

 FDA issues approval for new, prescription medication to control postoperative pain associated with surgical procedures in cats, expanding Elanco’s pain portfolio.

With the U.S. Food and Drug Administration (FDA) approval of Zorbium™ (buprenorphine transdermal solution), Elanco Animal Health (NYSE: ELAN) expands its pain management offerings while addressing an unmet need for veterinary practices.

A new long-acting medication to control postoperative pain associated with surgical procedures in cats, ZORBIUM provides up to four days of pain control from a single transdermal dose. ZORBIUM is an innovative, transdermal formulation of a commonly used opioid (buprenorphine) in cats, enabling veterinarians to provide consistent, reliable pain relief to their post-op feline patients for 4 days without relying upon owners to administer an opioid after discharge and without the need for repeat injections. Consistent pain control reassures cat owners and reduces the challenges of administering pain medications at home.

https://finance.yahoo.com/news/elanco-zorbium-buprenorphine-transdermal-solution-213000984.html